Hypermethylated 14-3-3-σ and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Zurita, Mercedes ^b   Lara, Pedro C ^c   del Moral, Rosario ^b   Torres, Blanca ^d   Linares Fernández, José L ^a   Arrabal, Sandra R ^a   Martínez Galán, Joaquina ^b   Oliver, Francisco J ^e   Ruiz de Almodóvar, José M ^a,d  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^d HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^e INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DNA; ESTROGEN RECEPTOR ALPHA; STRATIFIN; ESR1 PROTEIN, HUMAN; EXONUCLEASE; SFN PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA METHYLATION; DNA MODIFICATION; FEMALE; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BLOOD; BREAST TUMOR; CANCER STAGING; CARCINOMA; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENETICS; METASTASIS; PATHOLOGY; PREDICTION AND FORECASTING; SPAIN; TIME; TREATMENT OUTCOME;

BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA, NEOPLASM; ESTROGEN RECEPTOR ALPHA; EXONUCLEASES; FEMALE; HUMANS; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; SPAIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954056411     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-217     Document Type: Article

References (45)

1. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 2004, 31(Suppl 1):S149-161. 10.1007/s00259-004-1538-5, 15107948.
2. Lopez E, Nunez MI, Guerrero MR, del Moral R, de Dios Luna J, del Mar Rodriguez M, Valenzuela MT, Villalobos M, Ruiz de Almodovar JM. Breast cancer acute radiotherapy morbidity evaluated by different scoring systems. Breast Cancer Res Treat 2002, 73(2):127-134. 10.1023/A:1015296607061, 12088115.
3. Pinar B, Lara PC, Lloret M, Bordon E, Nunez MI, Villalobos M, Guerrero R, Luna JD, Ruiz de Almodovar JM. Radiation-induced DNA damage as a predictor of long-term toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy. Radiat Res 2007, 168(4):415-422. 10.1667/RR0746.1, 17903032.
4. Ruiz-Garcia J, Ruiz de Almodovar JM, Olea N, Pedraza V. Thyroglobulin level as a predictive factor of tumoral recurrence in differentiated thyroid cancer. J Nucl Med 1991, 32(3):395-398.
5. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 1998, 52(1-3):239-259. 10.1023/A:1006137619153, 10066086.
6. Esteller M. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol 2005, 205(2):172-180. 10.1002/path.1707, 15643671.
7. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 1997, 75(6):429-439. 10.1007/s001090050128, 9231883.
8. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S, Erkek E, Bozdogan O, Peinado H, Niveleau A, Mao JH, Balmain A, Cano A, Esteller M. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res 2004, 64(16):5527-5534. 10.1158/0008-5472.CAN-03-4061, 15313885.
9. Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, Herman JG, Gabrielson E. Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res 2004, 10(18 Pt 1):5998-6005. 10.1158/1078-0432.CCR-04-0667, 15447983.
10. Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, Cruz MA, Cantos B, Provencio M, Espana P, Bonilla F. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 2004, 41(2):117-124. 10.1002/gcc.20062, 15287024.
11. Martinez-Galan J, Torres B, Del Moral R, Munoz-Gamez JA, Martin-Oliva D, Villalobos M, Nunez MI, Luna J de D, Oliver FJ, Ruiz de Almodovar JM. Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther 2008, 7(6):958-965. 10.4161/cbt.7.6.5966, 18379196.
12. Auwera I, Elst HJ, Van Laere SJ, Maes H, Huget P, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer 2009, 100(8):1277-1286. 10.1038/sj.bjc.6605013, 2676551, 19367284.
13. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005, 2(Suppl 1):S4-11. 10.1038/ncponc0354, 16341240.
14. Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, Jones PA, Laird PW. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004, 64(11):3807-3813. 10.1158/0008-5472.CAN-03-3852, 15172987.
15. Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 2001, 61(6):2782-2787.
16. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001, 357(9265):1335-1336. 10.1016/S0140-6736(00)04501-3, 11343741.
17. Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, Sukumar S, Argani P. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003, 107(6):970-975. 10.1002/ijc.11508, 14601057.
18. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008, 14(7):1938-1946. 10.1158/1078-0432.CCR-07-4082, 18381931.
19. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93(18):9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
20. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000, 97(11):6049-6054. 10.1073/pnas.100566997, 18556, 10811911.
21. Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherguina I, Fujimoto S, Dahiya R. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 2002, 94(5):384-390.
22. Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N, Baylin SB. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 2008, 5(5):e114. 10.1371/journal.pmed.0050114, 2429944, 18507500.
23. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001, 20(26):3348-3353. 10.1038/sj.onc.1204438, 11423985.
24. Jeronimo C, Monteiro P, Henrique R, Dinis-Ribeiro M, Costa I, Costa VL, Filipe L, Carvalho AL, Hoque MO, Pais I, Leal C, Teixeira MR, Sidransky D. Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat 2008, 109(1):27-34. 10.1007/s10549-007-9620-x, 17549626.
25. Jacinto FV, Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 2007, 22(4):247-253. 10.1093/mutage/gem009, 17412712.
26. Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM, Yaffe MB. 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature 2007, 446(7133):329-332. 10.1038/nature05584, 17361185.
27. Valenzuela MT, Mateos S, Ruiz de Almodovar JM, McMillan TJ. Variation in sensitizing effect of caffeine in human tumour cell lines after gamma-irradiation. Radiother Oncol 2000, 54(3):261-271. 10.1016/S0167-8140(99)00180-2, 10738085.
28. Valenzuela MT, Guerrero R, Nunez MI, Ruiz De Almodovar JM, Sarker M, de Murcia G, Oliver FJ. PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene 2002, 21(7):1108-1116. 10.1038/sj.onc.1205169, 11850828.
29. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y, Inoue S. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 2002, 417(6891):871-875. 10.1038/nature00826, 12075357.
30. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007, 9(4):R57. 10.1186/bcr1762, 2206733, 17764565.
31. Dillon RL, Brown ST, Ling C, Shioda T, Muller WJ. An EGR2/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancer. Mol Cell Biol 2007, 27(24):8648-8657. 10.1128/MCB.00866-07, 2169423, 17938205.
32. Niemantsverdriet M, Wagner K, Visser M, Backendorf C. Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 2008, 27(9):1315-1319. 10.1038/sj.onc.1210742, 17704798.
33. Wilker EW, Grant RA, Artim SC, Yaffe MB. A structural basis for 14-3-3sigma functional specificity. J Biol Chem 2005, 280(19):18891-18898. 10.1074/jbc.M500982200, 15731107.
34. Chu K, Teele N, Dewey MW, Albright N, Dewey WC. Computerized video time lapse study of cell cycle delay and arrest, mitotic catastrophe, apoptosis and clonogenic survival in irradiated 14-3-3sigma and CDKN1A (p21) knockout cell lines. Radiat Res 2004, 162(3):270-286. 10.1667/RR3221, 15332997.
35. Rajagopalan S, Sade RS, Townsley FM, Fersht AR. Mechanistic differences in the transcriptional activation of p53 by 14-3-3 isoforms. Nucleic Acids Res 38(3):893-906. 10.1093/nar/gkp1041, 2817464, 19933256.
36. Schumacher B, Mondry J, Thiel P, Weyand M, Ottmann C. Structure of the p53 C-terminus bound to 14-3-3: Implications for stabilization of the p53 tetramer. FEBS Lett 2010, 584:1443-8. 10.1016/j.febslet.2010.02.065, 20206173.
37. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 2000, 19(46):5298-5302. 10.1038/sj.onc.1203898, 11077447.
38. Castedo M, Perfettini JL, Roumier T, Yakushijin K, Horne D, Medema R, Kroemer G. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 2004, 23(25):4353-4361. 10.1038/sj.onc.1207573, 15048074.
39. Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo Y, Guo Y. Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res 2008, 14(21):7050-7059. 10.1158/1078-0432.CCR-08-0520, 18981002.
40. Rodenhiser DI. Epigenetic contributions to cancer metastasis. Clin Exp Metastasis 2009, 26(1):5-18. 10.1007/s10585-008-9166-2, 18386135.
41. Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD, Euhus DM. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 2005, 11(1):166-172.
42. Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D. 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res 2008, 68(6):1760-1767. 10.1158/0008-5472.CAN-07-3177, 18339856.
43. Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC, Yu D. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 2009, 69(8):3425-3432. 10.1158/0008-5472.CAN-08-2765, 2671640, 19318578.
44. Issa JP. Age-related epigenetic changes and the immune system. Clin Immunol 2003, 109(1):103-108. 10.1016/S1521-6616(03)00203-1, 14585281.
45. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008, 26(12):1987-1992. 10.1200/JCO.2007.10.8407, 18421050.